Hologic, Inc. (NASDAQ:HOLX) Receives Consensus Rating of “Hold” from Analysts

Hologic, Inc. (NASDAQ:HOLX) has earned an average rating of “Hold” from the seventeen brokerages that are presently covering the firm, MarketBeat reports. Eleven investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $84.62.

Several research firms have recently issued reports on HOLX. BNP Paribas upgraded shares of Hologic to a “strong-buy” rating in a research note on Tuesday, December 10th. Leerink Partners lowered shares of Hologic from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $80.00 to $75.00 in a research note on Thursday, February 6th. Royal Bank of Canada dropped their target price on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a research report on Thursday, February 6th. Stephens reaffirmed an “overweight” rating and issued a $84.00 target price on shares of Hologic in a report on Thursday, February 6th. Finally, Raymond James reiterated an “outperform” rating and set a $90.00 price target (down from $95.00) on shares of Hologic in a report on Thursday, February 6th.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. General Partner Inc. bought a new position in shares of Hologic in the fourth quarter worth $26,000. Groupama Asset Managment boosted its stake in Hologic by 9.9% in the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 2,999 shares during the period. Venturi Wealth Management LLC grew its holdings in Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after buying an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Hologic by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock valued at $42,000 after buying an additional 260 shares during the period. Finally, Smartleaf Asset Management LLC lifted its holdings in shares of Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after buying an additional 159 shares in the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Price Performance

Shares of NASDAQ:HOLX opened at $61.77 on Tuesday. Hologic has a twelve month low of $60.34 and a twelve month high of $84.67. The stock’s 50 day moving average is $65.08 and its 200-day moving average is $73.11. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $13.86 billion, a price-to-earnings ratio of 19.49, a PEG ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Sell-side analysts forecast that Hologic will post 4.28 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.